Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SHR-1701 |
Synonyms | |
Therapy Description |
SHR-1701 is a monoclonal anti-PD-L1 antibody fused to the extracellular domain of Tgfbr2, which may trap TGFbeta and block TGFbeta-mediated immune suppression, leading to enhanced response to PD-L1 inhibition (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 9055-9055). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SHR-1701 | SHR 1701|SHR1701|Retlirafusp Alfa | Immune Checkpoint Inhibitor 149 PD-L1 Inhibitor 13 TGFB inhibitor 5 | SHR-1701 is a monoclonal anti-PD-L1 antibody fused to the extracellular domain of Tgfbr2, which may trap TGFbeta and block TGFbeta-mediated immune suppression, leading to enhanced response to PD-L1 inhibition (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 9055-9055). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04324814 | Phase I | SHR-1701 | A Trial of SHR-1701 in Subjects With Advanced Solid Tumors | Completed | AUS | 0 |